KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Alnylam Pharmaceuticals (ALNY) Cash & Equivalents (2016 - 2025)

Alnylam Pharmaceuticals' Cash & Equivalents history spans 17 years, with the latest figure at $1.7 billion for Q4 2025.

  • For Q4 2025, Cash & Equivalents rose 71.48% year-over-year to $1.7 billion; the TTM value through Dec 2025 reached $1.7 billion, up 71.48%, while the annual FY2025 figure was $1.7 billion, 71.48% up from the prior year.
  • Cash & Equivalents reached $1.7 billion in Q4 2025 per ALNY's latest filing, up from $1.5 billion in the prior quarter.
  • In the past five years, Cash & Equivalents ranged from a high of $1.7 billion in Q4 2025 to a low of $379.5 million in Q1 2021.
  • Average Cash & Equivalents over 5 years is $913.3 million, with a median of $917.5 million recorded in 2022.
  • Peak YoY movement for Cash & Equivalents: soared 120.25% in 2021, then decreased 22.82% in 2022.
  • A 5-year view of Cash & Equivalents shows it stood at $822.2 million in 2021, then increased by 5.64% to $868.6 million in 2022, then fell by 6.43% to $812.7 million in 2023, then rose by 18.92% to $966.4 million in 2024, then soared by 71.48% to $1.7 billion in 2025.
  • Per Business Quant, the three most recent readings for ALNY's Cash & Equivalents are $1.7 billion (Q4 2025), $1.5 billion (Q3 2025), and $1.1 billion (Q2 2025).